Security Snapshot

Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) Institutional Ownership

CUSIP: 23255M204

13F Institutional Holders and Ownership History from Q1 2023 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

18

Shares (Excl. Options)

296,254

Price

$1.27

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock, no par value
Symbol
CYCN on Nasdaq
Shares outstanding
3,367,000
Price per share
$1.55
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
296,254
Total reported value
$376,255
% of total 13F portfolios
0%
Share change
+37,995
Value change
+$3,325
Number of holders
18
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • CYCN - Cyclerion Therapeutics, Inc. - Common Stock, no par value is tracked under CUSIP 23255M204.
  • 18 institutions reported positions in Q4 2025.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 18 to 1 between Q4 2025 and Q1 2026.
  • Reported value moved from $376,255 to $155.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 18 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 23255M204?
CUSIP 23255M204 identifies CYCN - Cyclerion Therapeutics, Inc. - Common Stock, no par value in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Hecht Peter M 28% $3,803,918 1,028,086 Peter M. Hecht 25 Mar 2025
J. WOOD CAPITAL ADVISORS LLC 5.4% $496,363 181,818 J. Wood Capital Advisors LLC 25 Mar 2025
TYNDALL CAPITAL PARTNERS L P 4.8% -6% $487,287 -$30,113 155,187 -5.8% Tyndall Capital Partners, L.P. 30 Jun 2025
American Endowment Foundation 4.9% $492,196 133,026 American Endowment Foundation 31 Dec 2024
FMR LLC 0.2% $17,538 4,740 FMR LLC 31 Dec 2024

As of 31 Dec 2025, 18 institutional investors reported holding 296,254 shares of Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN). This represents 8.8% of the company’s total 3,367,000 outstanding shares.

Institutional Holders of Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 100 $155 $1.55 1
2025 Q4 296,254 $376,255 +$3,325 $1.27 18
2025 Q3 258,836 $595,353 -$333,887 $2.30 17
2025 Q2 362,816 $1,055,824 -$30,767 $2.91 17
2025 Q1 373,392 $931,696 -$29,342 $2.50 18
2024 Q4 382,073 $1,230,314 -$1,793,165 $3.22 19
2024 Q3 1,042,639 $2,696,608 -$289,148 $2.59 15
2024 Q2 1,051,710 $2,411,691 -$42,676 $2.30 17
2024 Q1 1,070,254 $3,424,719 +$2,411 $3.20 15
2023 Q4 1,069,490 $3,583,217 -$8,652 $3.35 15
2023 Q3 1,072,275 $3,658,805 +$244,093 $3.42 17
2023 Q2 995,440 $4,096,493 +$4,096,489 $4.12 17
2023 Q1 10 $4 +$4 $0.40 1